Researchers gather in newly launched research initiative for precision medicine
This is a translation of an article from Genomic Medicine Sweden (GMS).
At the end of October, more than a hundred researchers gathered for the first Precision Omics Initiative Sweden (PROMISE) symposium. The symposium launched the new research initiative for precision medicine and omics data in Sweden.
The goal of PROMISE is to integrate medical research and healthcare, data, and modern technology, thereby strengthening Sweden’s position in precision medicine. The initiative is led by SciLifeLab and Genomic Medicine Sweden (GMS).
Tuuli Lappalainen, director of the SciLifeLab National Genomics Infrastructure (NGI) and professor at KTH, opened the conference and spoke about the PROMISE initiative.
“This is the right time for an initiative like PROMISE. The building blocks are already in place in Sweden, and PROMISE can accelerate how we build large data resources to study various diseases using new technologies and AI. The goal is then to translate omics technologies into healthcare, thereby improving diagnostics and treatments,” explained Tuuli Lappalainen.
PROMISE focuses on three central areas
- Large-scale research data on rare diagnoses, cancer, and common diseases. Data from both patients and the general population will be generated to create a broader foundation for research and personalized care.
- National data management infrastructure to facilitate research use and improve sharing and access to multi-omics data in healthcare across the country.
- Legal and regulatory frameworks. Adaptation to modern requirements to utilize Sweden’s potential in precision medicine.
“This is a research initiative where GMS, SciLifeLab, and many others are building on national efforts and projects to reach the next level of precision health,” says Richard Rosenquist Brandell, director of GMS.
